Author:
Wan Sheng,Xu Wen,Xie Bo,Guan Cuiping,Song Xiuzu
Abstract
Cytotoxic T lymphocyte has been a concern for the etiopathogenesis of alopecia areata (AA), some recent evidence suggests that the regulatory T (Treg) cell deficiency is also a contributing factor. In the lesional scalp of AA, Treg cells residing in the follicles are impaired, leading to dysregulated local immunity and hair follicle (HF) regeneration disorders. New strategies are emerging to modulate Treg cells’ number and function for autoimmune diseases. There is much interest to boost Treg cells in AA patients to suppress the abnormal autoimmunity of HF and stimulate hair regeneration. With few satisfactory therapeutic regimens available for AA, Treg cell-based therapies could be the way forward. Specifically, CAR-Treg cells and novel formulations of low-dose IL-2 are the alternatives.
Subject
Immunology,Immunology and Allergy
Reference189 articles.
1. Incidence of alopecia areata in Olmsted county, Minnesota, 1975 through 1989;Safavi;Mayo Clin Proc,1995
2. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis;Lee;J Am Acad Dermatol,2020
3. Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review;Toussi;J Am Acad Dermatol,2021
4. Hair follicle immune privilege and its collapse in alopecia areata;Bertolini;Exp Dermatol,2020
5. Novel therapies for alopecia areata: the era of rational drug development;Wang;J Allergy Clin Immunol,2018